Abbott Laboratories (ABT)
NYSE: ABT
· Real-Time Price · USD
132.14
3.58 (2.78%)
At close: May 15, 2025, 12:42 PM
Abbott Laboratories Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostic Products Revenue | 9.34B | 9.99B | 16.58B | 15.64B | 10.8B | 7.71B | 7.5B | 5.62B | 4.81B | 4.65B | 4.72B | 4.54B | 4.29B | 4.13B |
| Diagnostic Products Revenue Growth | -6.48% | -39.77% | +6.01% | +44.78% | +40.09% | +2.91% | +33.46% | +16.68% | +3.59% | -1.59% | +3.87% | +5.89% | +4.02% | n/a |
| Established Pharmaceutical Products Revenue | 5.19B | 5.07B | 4.91B | 4.72B | 4.3B | 4.49B | 4.42B | 4.29B | 3.86B | 3.72B | 3.12B | 4.97B | 23.13B | 22.43B |
| Established Pharmaceutical Products Revenue Growth | +2.53% | +3.14% | +4.11% | +9.64% | -4.08% | +1.45% | +3.15% | +11.09% | +3.74% | +19.31% | -37.31% | -78.50% | +3.11% | n/a |
| Medical Devices Revenue | 18.99B | 16.89B | 14.69B | 14.37B | 11.79B | 12.24B | 7.23B | 6.92B | 6.9B | 6.97B | 6.95B | 6.74B | 6.47B | 6.01B |
| Medical Devices Revenue Growth | +12.43% | +14.98% | +2.23% | +21.89% | -3.69% | +69.30% | +4.39% | +0.38% | -1.09% | +0.32% | +3.16% | +4.16% | +7.74% | n/a |
| Nutritional Products Revenue | 8.41B | 8.15B | 7.46B | 8.29B | 7.65B | 7.41B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Nutritional Products Revenue Growth | +3.18% | +9.32% | -10.07% | +8.46% | +3.21% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 3.06B | 2.91B | 2.9B | 2.92B | 2.94B | 2.7B | 2.6B | 2.62B | 2.62B | 2.97B | 2.73B | 2.76B | 2.79B | 3.05B | 2.77B | 2.73B | 2.78B | 2.57B | 2.3B | 2.28B | 2.55B | 2.41B | 2.44B | 2.43B | 2.48B | 2.36B | 2.38B | 2.47B | 2.54B | 2.46B | 2.1B | 2.13B | 2.42B | 1.61B | 1.63B | 1.74B | 1.7B | 1.66B | 1.67B | 1.73B | 1.74B |
| Selling, General, and Administrative Revenue Growth | +5.30% | +0.41% | -0.69% | -0.95% | +8.84% | +3.96% | -0.69% | +0.15% | -12.04% | +8.86% | -0.94% | -1.08% | -8.56% | +10.16% | +1.50% | -2.05% | +8.29% | +11.64% | +1.14% | -10.68% | +5.59% | -1.11% | +0.25% | -1.78% | +5.04% | -0.76% | -3.61% | -2.99% | +3.25% | +17.29% | -1.55% | -12.05% | +50.65% | -1.17% | -6.28% | +2.30% | +2.60% | -0.66% | -3.53% | -0.58% | n/a |
| Research and Development Revenue | 716M | 754M | 713M | 698M | 679M | 690M | 672M | 715M | 654M | 725M | 782M | 684M | 697M | 762M | 672M | 654M | 654M | 698M | 580M | 564M | 578M | 595M | 596M | 577M | 672M | 562M | 574M | 575M | 589M | 613M | 562M | 513M | 547M | 343M | 352M | 348M | 379M | 369M | 378M | 345M | 313M |
| Research and Development Revenue Growth | -5.04% | +5.75% | +2.15% | +2.80% | -1.59% | +2.68% | -6.01% | +9.33% | -9.79% | -7.29% | +14.33% | -1.87% | -8.53% | +13.39% | +2.75% | 0.00% | -6.30% | +20.34% | +2.84% | -2.42% | -2.86% | -0.17% | +3.29% | -14.14% | +19.57% | -2.09% | -0.17% | -2.38% | -3.92% | +9.07% | +9.55% | -6.22% | +59.48% | -2.56% | +1.15% | -8.18% | +2.71% | -2.38% | +9.57% | +10.22% | n/a |